We go beyond medicine, using our resources to improve health care in our local communities and across the globe.
At AbbVie, we value our partnership with patient organizations as part of our commitment to maintaining a patient-focused approach in healthcare. We believe healthcare should prioritize prevention, treatment, and managing diseases, ensuring everyone gets access to quality medicines, services, and information. We support the importance of ensuring that patient organizations operate independently. It ensures that they can serve the needs of the patients and caregivers they represent.
Patient organizations play an important role in supporting patients and their family throughout their healthcare journey, offering education and various services. They act as a voice for patients, advocating for their needs and interests within the healthcare system, research, and access to care.
We have a dedicated Patient Engagement team that focuses on building meaningful collaborations with various groups, including patient organizations. This team's efforts support a variety of programs, tools, and initiatives aimed at improving healthcare outcomes and addressing the needs of patients throughout their journey. AbbVie is committed to supporting patients & care partners, reinforcing our patient-focused approach in healthcare.
Engaging with patient organizations creates opportunities for collaboration aimed at improving healthcare by addressing unmet needs and enhancing patient support through research, diagnosis, treatment, and beyond.
By sharing insights and experiences, these organizations provide a deeper understanding of patient challenges. This collaboration fosters discussions and ideas to evolve the healthcare landscape, aiming to build trust, understanding, and shared objectives for better health outcomes.
We follow the Innovative Medicine Canada (IMC) Code of ethical practices. To learn more, we encourage you to visit section 3.3 - Guidelines for transparency in funding of patient and advocacy groups and patient associations (including annex A) from the 2022 Code of Ethical Practices document listed on the Innovative Medicines Canada Web site.
You will be leaving your country’s AbbVie site and will be redirected to another country’s website. The AbbVie’s web site to where you will be redirected is exclusively designed for residents of particularly one or various countries, as announced in such web site. As a result, the website where you will be directed may contain pharmaceutical products information or other information that is not approved in other countries, regions or even in your country or territory of reference. If you live in a country other than those to which the site is directed, please contact your local AbbVie affiliate for the correct information on the products of your country of residence.